Abstract | INTRODUCTION: METHODS: Patients who had histologically confirmed metastatic gastric cancer refractory to ≥ two previous chemotherapy regimens were included. The primary endpoint was the overall response rate (ORR) by an independent central review. According to an assumption of a threshold ORR of 10% and expected ORR of 25%, with α = 0.05 and β = 0.20, at least 33 patients were required. The secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life measured by EQ-5D, and safety. RESULTS: Among the 35 enrolled patients, 33 were included in the primary analysis. All patients previously received fluoropyrimidines, cisplatin, and taxanes, and 24 (73%) were pretreated with irinotecan. The confirmed ORR was 27% [95% confidence interval (CI) 13-46]. The median PFS and OS were 2.2 (95% CI 1.2-3.2) and 5.6 (95% CI 4.1-7.0) months, respectively. In the multivariate analyses, immunotherapy within 90 days and a Glasgow Prognostic Score of 0 were associated with better treatment outcomes. The most common grade ≥ 3 adverse event was neutropenia (36%), and no febrile neutropenia was observed. The median EQ-5D scores did not change from baseline at 2, 4, and 8 weeks (p value = 0.38, 0.79, and 0.98, respectively). CONCLUSION: Modified FOLFOX6 (mFOLFOX6) showed substantial activity and acceptable toxicity for chemotherapy-refractory advanced gastric cancer. TRIAL REGISTRATION: UMIN Clinical Trial Registry (UMIN000016416).
|
Authors | Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Chihiro Kondoh, Isao Oze, Kyoko Kato, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Tsutomu Tanaka, Masahiro Tajika, Kei Muro |
Journal | Advances in therapy
(Adv Ther)
Vol. 37
Issue 6
Pg. 2853-2864
(06 2020)
ISSN: 1865-8652 [Electronic] United States |
PMID | 32378071
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Organoplatinum Compounds
- Oxaliplatin
- Leucovorin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Fluorouracil
(therapeutic use)
- Humans
- Leucovorin
(therapeutic use)
- Male
- Middle Aged
- Organoplatinum Compounds
(therapeutic use)
- Oxaliplatin
(therapeutic use)
- Progression-Free Survival
- Stomach Neoplasms
(drug therapy)
- Treatment Outcome
|